EcoDrugPlus

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSAMXG00000042966
Gene Symbol: KCNQ2A
1 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSAMXG00000010316
Gene Symbol: KCNH2A
1 Cross references
178 Possible Orthologues:

Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 4-Like

Ensembl ID : ENSAMXG00000038566
Gene Symbol: LOC103046025
2 Cross references
207 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSAMXG00000029082
Gene Symbol: PSENEN
3 Cross references
185 Possible Orthologues:

Presenilin-1

Ensembl ID : ENSAMXG00000013813
Gene Symbol: LOC103047839
3 Cross references
202 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSAMXG00000024339
Gene Symbol: LOC103033121
3 Cross references
413 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSAMXG00000033437
Gene Symbol: LOC103046670
3 Cross references
307 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSAMXG00000032804
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSAMXG00000009441
Gene Symbol: PTGDR2
2 Cross references
145 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSAMXG00000037178
Gene Symbol: PTGER1A
1 Cross references
171 Possible Orthologues:

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSAMXG00000031327
Gene Symbol: PTGER1B
1 Cross references
163 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSAMXG00000030985
Gene Symbol: PTGER3
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).